3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thromboembolism
2
Pulmonary Embolism
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Carboplatin
171
Paclitaxel
129
Radiotherapy
119
Cisplatin
109
Docetaxel
93
Gemcitabine
81
Erlotinib Hydrochloride
80
Pemetrexed
78
Bevacizumab
56
Etoposide
41
pembrolizumab
36
Gefitinib
32
Vinorelbine
31
Topotecan
30
Surveys and Questionnaires
29
Irinotecan
28
Radiosurgery
21
Nivolumab
20
Drug Therapy
20
Magnetic Resonance Spectroscopy
18
Cetuximab
18
durvalumab
17
Early Intervention, Educational
17
Blood Specimen Collection
17
Surgical Procedures, Operative
16
Cyclophosphamide
16
Celecoxib
15
Ipilimumab
14
Immunohistochemistry
14
Filgrastim
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Lung Neoplasms
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled
NCT00475098
2016-09-02
TILT
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
553 enrolled